Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
serplulimab + FOLFOXIRI
- Development stage
- Preclinical
- Lead developer
- Henlius
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Serplulimab + FOLFOXIRI is an investigational combination therapy for cancer, particularly metastatic colorectal cancer. Serplulimab is a humanized monoclonal antibody targeting programmed cell death protein 1 (PD-1), functioning as an immune checkpoint inhibitor to enhance T-cell mediated anti-tumor responses. It is developed by Henlius and marketed under the brand name HANSIZHUANG. FOLFOXIRI is a chemotherapy regimen consisting of four drugs: folinic acid (leucovorin), fluorouracil, oxaliplatin, and irinotecan. This regimen acts through multiple mechanisms—antimetabolite activity from fluorouracil, DNA crosslinking from oxaliplatin, topoisomerase I inhibition from irinotecan, and modulation of fluorouracil toxicity by leucovorin—to inhibit tumor growth and proliferation[6][5]. The combination aims to leverage both immunotherapy and cytotoxic chemotherapy for enhanced efficacy in advanced or metastatic colorectal cancer.
- Brand names
- HANSIZHUANG
- Other names
- HetroniflyFOLFOXIRI
02
Targets
TOP1 (DNA Topoisomerase I)TS (Thymidylate synthase)DNAPDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on serplulimab + FOLFOXIRI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on serplulimab + FOLFOXIRI.